Brain-derived neurotrophic factor gene polymorphism in post-ST-elevation myocardial infarction patients undergoing primary percutaneous intervention

Abstract

The goal of this study was to elucidate a link of brain-derived neurotrophic factor(BDNF) Val66Met gene with combined 6-month clinical end points in post-myocardial infarction patients. Methods: 256 post-myocardial infarction patients who underwent primary percutaneouscoronary intervention were enrolled in the study. Variants of Val66Met gene BDNF were identifiedby real-time polymerase chain reaction at baseline.Results: The combined clinical end points (major cardiovascular events and hospitalization) were determined in 61 (23.8%) post-STEMI patients;consequently, 195 (76.2%) patients did not meet the events. Univariate linear regression revealed that predictors for combined clinical end points were peak TnI levels, NT-proBNP, SYNTAX score,TIMI score, obesity, left ventricular ejection fraction, and genotype 66ValMet+66MetMet in BDNFgene. The cumulative clinical outcomes (major adverse cardiac events and admission) were deter-mined in 61 (23.8%) patients. Kaplan-Meier curves demonstrated that 66ValVal genotype of BDNFgene was significantly associated with the low number of combined end points.Conclusion: The Val66Met polymorphism in BDNF gene independently predicted 6-month combined clinical endpoints in post-myocardial infarction patients.